Company

Product

Description

Indication

Status

Phase I

Arch Biopartners Inc., of Toronto

Metablok

Peptide that blocks dipeptidase-1

Healthy volunteers (eventually inflammation, sepsis and cancer metastasis)

Started the single ascending dose arm of the 44-subject study to test the safety and pharmacokinetic profile of the drug; results expected later in 2019

Hutchison China Meditech Ltd., of London

HMPL-523

Spleen tyrosine kinase inhibitor

Immune thrombocytopenia

First patient dosed in study testing the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-523; the study, which will enroll 50-60 patients, includes a dose escalation stage and a dose expansion stage

Phase II

Beyondspring Inc., of New York

Plinabulin 

Sequesters tubulin heterodimers

Neutropenia

In the phase II portion of the BPI-2358-105 study, the 20-mg/m2 dose over four treatment cycles improved patient reported quality of life measurements for global health status (p<0.0001), symptom scale (p<0.009), summary score (p<0.02), fatigue (p<0.03), pain (p<0.03) and insomnia (p<0.05)

Tenax Therapeutics Inc., of Morrisville, N.C.

Levosimendan

Calcium sensitizer

Pulmonary hypertension and heart failure with preserved ejection fraction

The HELP study has enrolled 8 of 36 expected patients; 3 patients have completed the 6-week protocol and have rolled over to the 2-year extension study; study has 12 activated sites with 3 additional sites expected to be activated over the next few weeks; top-line data expected in the first quarter of 2020


Notes

For more information about individual companies and/or products, see Cortellis.

 

No Comments